<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142297</url>
  </required_header>
  <id_info>
    <org_study_id>08-0156H</org_study_id>
    <nct_id>NCT01142297</nct_id>
  </id_info>
  <brief_title>Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Controlled Trial Comparing the Stability of SLA Implants and SLActive Implants Using Resonance Frequency Analysis for Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the patterns of dental implant stabilization between a standard and
      chemically modified implant surface in patients with type 2 diabetes. It is hypothesized that
      the chemically modified surface will enhance early healing events (first 4 months following
      placement)in diabetes patients with compromises in rate of implant integration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized study design whereby type 2 diabetic patients will receive 2
      implants in the mandible or maxilla to assess implant integration. One implant will be a
      regular SLA implant; the other will have a SLActive surface. The primary objective of this
      randomized controlled study is to evaluate the stability of Straumann 4.1 mm diameter
      implants in the posterior mandible or maxilla of type 2 diabetic patients during the first 12
      weeks after implantation using resonance frequency analysis. The control implant is a
      standard Straumann implant with an SLA® surface and the test implant the same implant design
      with SLActive® surface. Assessments will utilize resonance frequency analysis (RFA), as a
      measure of implant integration, and clinical outcomes of implant success. This study will
      enroll type 2 diabetes patients having glycated hemoglobin (HbA1c) levels from 8.0% to 12% at
      baseline.

      The primary objective is to test for statistically significant differences in ISQ values
      between the test and control implants at 2, 3, 4, 6, 7, 8 weeks and 3 months after surgery.
      If a difference of 2 Osstell RFA ISQ units is detected at any time point it will be
      considered that the implant having achieved the higher value is better osseointegrated. This
      split-mouth study design will assess changes in implant stability from baseline as the
      primary outcome at the implant level. This study will require 20 patients to detect this
      difference (SD=2.0 ISQ units) with a power of 80% at the P=0.05 level.

      Secondary objectives include:

        -  Implant survival and implant success at 1-year post loading.

        -  The nature and frequency of adverse events/complications between the 2 groups will be
           compared.

        -  Prosthesis success
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant Stability Quotient (ISQ)</measure>
    <time_frame>4 months</time_frame>
    <description>resonance frequency analysis employed to determine implant stability quotient on a 1-100 point scale with 100 representing the greatest stability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success of Implants</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Partially Edentulous Mandible</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>dental implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard SLA surface and chemically modified surface</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>dental implant and modified dental implant</intervention_name>
    <description>standard SLA surface and chemically modified surface</description>
    <arm_group_label>dental implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females must be at least 18 years of age, and having a diagnosis of type 2
             diabetes mellitus occurring over 1 year prior to enrollment (self-reported and
             verified with physician report, test results, and/or treatment record)

          -  Type 2 diabetic patients may be on a modified diet, oral medication, insulin, or
             combination therapies

          -  Glycated hemoglobin A1c (HbA1c) levels of at least 8.0% up to and including 12.0% as
             reported within 4 weeks of implant placement

          -  Have at least two missing teeth in the posterior mandible in FDI positions 4, 5, 6, or
             7

          -  The tooth at the implant site must have been extracted or lost at least 4 months
             before the date of implantation

          -  Adequate bone quantity at the implant site to permit the insertion of a Straumann
             Standard or Standard Plus 4.1 mm diameter implant at least 8 mm in length without the
             use of concurrent bone augmentation techniques, i.e. Implant insertion sites must have
             sufficient bone height such that the implant will not encroach on vital structures and
             sufficient width that a minimum of 1 mm lingual and buccal bone will remain

          -  Patients must have signed the informed consent form. They must be committed to the
             study. If the treating clinicians doubt that the patient is willing or will be able to
             attend all study follow-up visits then the patient should not be admitted to the study

        Exclusion Criteria:

          -  Patients with a history of systemic disease other than type 2 diabetes mellitus that
             may preclude dental implant therapy (including cardiovascular, hepatic, renal,
             gastrointestinal, metabolic, neurologic, pulmonary, endocrine, autoimmune, or
             psychiatric disorders)

          -  Presence of conditions requiring chronic routine prophylactic use of antibiotics
             (e.g., bacterial endocarditis, cardiac valvular anomalies, prosthetic joint
             replacements)

          -  Diabetic retinopathy requiring imminent or planned surgical intervention

          -  Diabetic neuropathy of sufficient severity as to require treatment for control of
             symptoms

          -  Serum creatinine &gt; 1.6 mg/dl

          -  AST (SGOT) or ALT (AGPT) &gt; 2 times upper limit of normal laboratory range

          -  Hypertension, with or without medications, having a systolic pressure &gt; 185mm Hg or
             diastolic pressure &gt; 105mm Hg

          -  Patient has significant untreated oral infections or inflammatory lesions

          -  Medical conditions requiring prolonged use of steroids

          -  History of leukocyte dysfunction and deficiencies

          -  History of bleeding disorders

          -  Patients with history of renal failure

          -  Patients with metabolic bone disorders

          -  Physical handicaps that would interfere with the ability to perform adequate oral
             hygiene

          -  Use of any investigational drug or device within the 30 day period immediately prior
             to implant surgery on study day 0

          -  Patients who smoke &gt;10 cigarettes per day or cigar equivalents, or who chew tobacco

          -  Conditions or circumstances, in the opinion of the investigator, which would prevent
             completion of study participation or interfere with analysis of study results, such as
             history of non-compliance, unreliability

        Local Factors:

          -  Signs of oral inflammation, such as untreated periodontitis around the teeth or
             erosive lichen planus in the non-tooth associated areas

          -  History of head/neck irradiation therapy

          -  Presence of bone defects in the jaw preventing implant placement

          -  Unhealed extraction sites (less than 4 months post extraction of teeth in intended
             sites)

          -  Bone surgery (bone grafts, guided tissue regeneration technique for bone enhancement)
             less than 6 months prior to implant placement

          -  Patients requiring bone grafting at the surgical sites at the time of surgery

          -  Severe teeth grinding or clenching habits

          -  Persistent intraoral infection

          -  Lack of sufficient stability of the implant at surgery to allow for proper healing.

          -  Patients with inadequate oral hygiene or unmotivated for adequate home care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>thomas w oates, dmd, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <results_first_submitted>October 27, 2014</results_first_submitted>
  <results_first_submitted_qc>December 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dental implant</keyword>
  <keyword>implant stabilization</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>glycated hemoglobin 8.0-12.0%</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dental Implant</title>
          <description>standard SLA surface and chemically-modified surface implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dental Implant</title>
          <description>standard SLA surface and chemically modified surface
dental implant : standard SLA surface and modified dental implant : chemically modified surface</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Implant Stability Quotient (ISQ)</title>
        <description>resonance frequency analysis employed to determine implant stability quotient on a 1-100 point scale with 100 representing the greatest stability.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SLA Minimum ISQ HbA1c&lt;9.5</title>
            <description>standard SLA surface
dental implant : standard SLA surface</description>
          </group>
          <group group_id="O2">
            <title>Modified SLA Minimum ISQ HbA1c&lt;9.5</title>
            <description>chemically modified surface
modified dental implant : chemically modified surface</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Stability Quotient (ISQ)</title>
          <description>resonance frequency analysis employed to determine implant stability quotient on a 1-100 point scale with 100 representing the greatest stability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="5.6"/>
                    <measurement group_id="O2" value="61.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success of Implants</title>
        <time_frame>1 year</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Clinical Success of Implants</title>
            <description>Successful outcome of implant after one year</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success of Implants</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dental Implant</title>
          <description>standard SLA surface
dental implant : standard SLA surface</description>
        </group>
        <group group_id="E2">
          <title>Modified Dental Implant</title>
          <description>chemically modified surface
modified dental implant : chemically modified surface</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas W. Oates</name_or_title>
      <organization>University of Texas Health Science Center at San Antonio</organization>
      <phone>210-567-3590</phone>
      <email>oates@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

